23B8A53B-83FD-47BB-AD6E-184E11B1E957
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 95.4993429697766
- age_years
- 48
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.492
- PROTEIN_SECRETION+0.471
- INTERFERON_ALPHA_RESPONSE+0.415
- OXIDATIVE_PHOSPHORYLATION+0.405
- HEDGEHOG_SIGNALING+0.401
- ADIPOGENESIS+0.369
- ANDROGEN_RESPONSE+0.352
- P53_PATHWAY+0.339
- MYC_TARGETS_V1+0.336
- NOTCH_SIGNALING+0.329
Top 10 suppressed
- KRAS_SIGNALING_DN-0.362
- SPERMATOGENESIS-0.252
- MYOGENESIS-0.072
- ANGIOGENESIS-0.067
- ALLOGRAFT_REJECTION-0.038
- APICAL_SURFACE+0.011
- COAGULATION+0.020
- APICAL_JUNCTION+0.023
- G2M_CHECKPOINT+0.045
- INFLAMMATORY_RESPONSE+0.048
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 37586AAC-159B-41F9-9078-C2F7888753AC | — | — | 0.922 |
| 2 | F5D36A14-8F2E-4C08-91BE-E3319784FF46 | — | — | 0.901 |
| 3 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.895 |
| 4 | 6F4F72B3-E2B1-48DD-B9F4-C03AFCE79566 | — | — | 0.892 |
| 5 | 69A8CCB7-91F2-475C-8A31-64CD4E075090 | — | — | 0.892 |
| 6 | E2C7E2B8-BC9B-476C-A705-CBBCA51F7C26 | — | — | 0.891 |
| 7 | A7D9F5B1-D8C2-440F-A0B7-8B5641C2DA66 | — | — | 0.886 |
| 8 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.886 |
| 9 | SRR934756 | — | — | 0.883 |
| 10 | 077523A7-E1C9-4E9F-8C9F-B9F647B4DF7C | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.492 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.471 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.415 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.405 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.401 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.369 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.352 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.339 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.336 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.329 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.324 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.321 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.315 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.313 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.311 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.301 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.291 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.283 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.283 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.282 | Temsirolimus | — uncovered |